Navigation Links
ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Date:9/4/2012

(telemetry, triplicate 12-lead ECGs, 24-hour Holter ECGs). Pharmacokinetic assessments were performed in each study and results demonstrate a favourable pharmacokinetic and pharmacodynamic profile, supporting oral, once-daily administration of E-52862.

The E-52862 Phase I programme is now complete and included over 300 human subjects (more than 250 received E-52862).  Results from the overall programme show favourable safety, tolerability, pharmacodynamic and pharmacokinetic profiles at all doses of E-52862 tested.

Today, the E-52862 clinical programme focuses on pain management - highlighting both neuropathic pain and the potentiation of opioid analgesia. The Phase II clinical trial programme for E-52862 began early in 2012.  The clinical project leader for E-52862, Roser Vives, M.D. commented that "Because of the MOA and data available to date, we are evaluating E-52862 in four different types of neuropathic pain and for treatment of pain in patients receiving opioids (for the enhancement of the analgesic effect and better tolerability). E-52862 also has potential applications for other neurological and psychiatric indications".

E-52862, whose MOA is both novel and complementary to that of other analgesic compounds, could provide a much-needed addition to future pain management choices with, perhaps, the option to be used as monotherapy, as well as in combination with other pain relief compounds, depending on the type of patient and clinical indication.

About ESTEVE

ESTEVE is a leading pharmaceutical chemical group based on Barcelona (Spain) with significant international presence.  Since it was founded in 1929, ESTEVE has been firmly committed to excellence in healthcare, dedicating efforts to innovative R&D of new medicines for unmet medical needs and focusing on high science and evidence-based research. ESTEVE has a strong partnership approach to drug discovery, development and commercialisation. The company
'/>"/>

SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ESTEVE Communicates its R&D Through a New Interactive Platform
2. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
5. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
6. Clinical Site Services, Industry Leader in Patient Enrollment Solutions, Announces New Website
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
9. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
10. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
(Date:9/30/2014)... 2014 OriginOil Inc. (OTC/QB: OOIL), developer ... to clean up large quantities of water, announced today ... reported on the launch of the company's CLEAN-FRACâ„¢ industrial ... by partner STW Resources . , Immediately upon ... day (bpd) and achieved a 99.8% reduction in Turbidity ...
(Date:9/30/2014)... 30, 2014 FemCap Inc., www.femcap.com  an ... receipt of a patent No: US, 8,795,248 B2 dated ... received FDA clearance in the U.S., 510(K) K121857, medical ... Europe. This patent is related to its menstrual cup with ... company is releasing FemmyCycle Teen, a third menstrual cup ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2The FemmyCycle 2
... NEW YORK, Nov. 6 Morria Biopharmaceuticals,Plc, a ... positive data from its ICH compliant Phase II ... from allergic,rhinitis. MRX-4 was given as an intranasal ... study was conducted in allergic,rhinitis patients outside of ...
... world leadership in the ... ingredients, - New S2383 flavor enhancer may be used in beverages, ... healthcare products to reduce the need for sucralose, ... (Nasdaq: SNMX ), a leading company,focused on using proprietary technologies ...
... NOVATO, Calif., Nov. 6 BioMarin,Pharmaceutical Inc. (Nasdaq: ... clinical,studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R),(galsulfase) and enzyme ... disease will be presented at the 58th Annual ... in Philadelphia,Pennsylvania, November 11-15, 2008., "We look ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 2Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 3
(Date:10/1/2014)... rainforests, prairies and forests of the world can also ... according to a surprising new study led by Colorado ... , The research team analyzed 596 soil samples collected ... stunning diversity of below-ground life, most of which had ... to 16.2 percent of the organisms discovered in the ...
(Date:9/30/2014)... is published today in the first authoritative scientific study ... on both sides of the grouse moor management debate. ... the Ecohydrology of River basins) project has shown that ... support red grouse populations for gun sports, has significant ... properties, river water chemistry and river ecology. , A ...
(Date:9/30/2014)... as something that we enjoy when we visit a national ... think of ourselves as a part of nature? A bird,s ... house? , The answers to these questions reflect different ... speech and in cultural artifacts. , A new Northwestern University ... Indian Center of Chicago and the Menominee tribe of Wisconsin, ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3Grouse moor burning causes widespread environmental changes 2The cultural side of science communication 2
... . , Halle/Saale. Invasive plant species can flourish ... origin. The reasons for this can be genetic changes or ... to adapt to the newcomers. These are the conclusions of ... their research on Buddleia or the Butterfly bush (Buddleja davidii) ...
... Stanford researchers have joined the ranks of investigators for ... 14 current HHMI investigators at Stanford, 11 of which ... HHMI investigators nationwide. Stanford,s recipients are: , ... applied physics. His research group is seeking to understand ...
... linked to lung disease may have a 70-percent to ... report in the May 26 issue of Archives of ... disorder, alpha1-antitrypsin deficiency (1ATD), is one of the most ... those of European descent, according to background information in ...
Cached Biology News:When the butterfly bush blossoms 2When the butterfly bush blossoms 34 Stanford faculty named Howard Hughes Medical Institute Investigators 2Genetic mutation associated with increased risk of lung cancer 2
...
... XT is undoubtedly the most complete and ... concept of layers and subsets makes it ... for different data outputs, for example Cy3 ... as well as different subsets of genes ...
...
...
Biology Products: